{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:53:34Z","timestamp":1761818014390,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jgo.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:09:57Z","timestamp":1555553397000},"page":"19-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies"],"prefix":"10.1016","volume":"11","author":[{"given":"Candida","family":"Vitale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"SEER data","key":"10.1016\/j.jgo.2019.04.002_bb0005"},{"issue":"25","key":"10.1016\/j.jgo.2019.04.002_bb0010","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2019.04.002_bb0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.jgo.2019.04.002_bb0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","article-title":"Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century","volume":"94","author":"Pulte","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jgo.2019.04.002_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2019.04.002_bb0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2019.04.002_bb0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"9980","key":"10.1016\/j.jgo.2019.04.002_bb0040","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jgo.2019.04.002_bb0045","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jgo.2019.04.002_bb0050","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus Chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2019.04.002_bb0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.jgo.2019.04.002_bb0060","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic Leukemia updating the National Cancer Institute-working group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jgo.2019.04.002_bb0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V120.21.719.719","article-title":"Phase II trial of Ofatumumab (OFA) for older patients and patients who refuse Fludarabine-based regimens with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","volume":"120","author":"Flinn","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jgo.2019.04.002_bb0070","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.24468","article-title":"A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"91","author":"Flinn","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2019.04.002_bb0075","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3109\/10428194.2014.974049","article-title":"A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia","volume":"56","author":"Strati","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.jgo.2019.04.002_bb0080","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V128.22.2041.2041","article-title":"Outcomes of Ibrutinib therapy by age in patients with CLL\/SLL: analyses from phase 3 trial data (RESONATE and RESONATE-2)","volume":"128","author":"Woyach","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jgo.2019.04.002_bb0085","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent Ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jgo.2019.04.002_bb0090","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819300335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819300335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:50:32Z","timestamp":1761817832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406819300335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1879406819300335"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2019.04.002","relation":{},"ISSN":["1879-4068"],"issn-type":[{"type":"print","value":"1879-4068"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}